http://www.pharmalot.com/// December 10th, 2008 // 7:23 am
Biotechs execs plan to visit Congress today to ask for a temporary change in the tax law that would let money-losing companies get cash from the government now, in exchange for tax credits they would pledge not to take if they eventually become profitable, The New York Times writes.
The change, if approved, could enable biotechs to receive potentially hundreds of millions or even billions of dollars, on the condition that the money would be used for R&D. The moves comes as many smaller biotechs face a severe cash shortage that is forcing them to dismiss workers, curtail research and even file for bankruptcy protection or liquidation. But prospects for the proposal are unclear.
Allyson Schwartz, a Democratic member of the House Ways and Means Committee, which handles tax matters, will push to include the proposal in the forthcoming economic stimulus package and expected many of her colleagues to view it favorably. “Innovation and technology are growth areas for American businesses and American workers and should be part of this package,” Schwartz, whose district in the Philadelphia area is home to some drugmakers and biotechs, tells the Times.